Focused On-demand Library for Kinesin-like protein KIF3B

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We use our state-of-the-art dedicated workflow for designing focused libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.







Alternative names:

HH0048; Microtubule plus end-directed kinesin motor 3B

Alternative UPACC:

O15066; B2RMP4; B4DSR5; E1P5M5


Kinesin-like protein KIF3B, also known as HH0048 and Microtubule plus end-directed kinesin motor 3B, is a microtubule-based molecular motor. It plays a crucial role in transporting intracellular cargos, such as vesicles, organelles, and protein complexes, by utilizing ATP hydrolysis. KIF3B is instrumental in cilia formation and maintaining photoreceptor integrity, specifically in rod photoreceptors, and facilitates the trafficking of vesicles containing NMDA receptor subunit GRIN2A into neuronal dendrites.

Therapeutic significance:

Given its involvement in Retinitis pigmentosa 89, a retinal dystrophy characterized by night vision blindness and loss of midperipheral visual field, Kinesin-like protein KIF3B presents a promising target for therapeutic intervention. Understanding the role of Kinesin-like protein KIF3B could open doors to potential therapeutic strategies for treating not only retinal dystrophies but also related ciliopathies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.